Dhanuka Agritech Q2 FY27 Net Profit Up 16.2% YoY

Event Type: The document contains the transcript of a post-results conference call held to discuss the Un-Audited Standalone and Consolidated Financial Results for the Quarter and Half-Year ended 30th September 2026 (Q2 FY27).

Date and Time: The conference call was held on 30th October 2026. The specific time and time zone were not disclosed in the provided transcript.

Purpose: The stated purpose was to discuss the company's financial performance for Q2 and H1 FY27, provide a strategic update on business operations, and address questions from analysts and investors.

Earnings Timing: The meeting was scheduled after the earnings announcement for Q2 FY27.

Management Participants: The following management representatives participated in the call:
Mr. M.K. Dhanuka – Chairman
Mr. Rahul Dhanuka – Managing Director
Mr. Harsh Dhanuka – Executive Director
Mr. V.K. Bansal – Chief Financial Officer

The call was hosted and moderated by Mr. Manish Mahawar from Antique Stock Broking Limited.

Availability of Materials: The document is the official transcript of the conference call, filed with the exchanges. There was no mention of a presentation deck, recording, or transcript being made available on a website, though the transcript itself was enclosed with this regulatory filing.

UPSI Statement: The transcript did not contain any explicit compliance language stating that no Unpublished Price Sensitive Information (UPSI) would be shared.

The management discussed the following key financial figures and strategic themes during the call:

Financial Period: Discussion focused on Q2 FY27 (Quarter ended 30th September 2026) and H1 FY27.

Financial Performance:
Revenue from Operations: Stood at INR 657.51 crores in Q2 FY27, compared to INR 598.24 crores in Q2 FY26, a growth of 9.91%.
EBITDA: Was INR 152.97 crores vs. INR 136.73 crores in Q2 FY26.
Profit After Tax (PAT): Stood at INR 109.22 crores vs. INR 93.97 crores in Q2 FY26, a growth of 16.2%.
Volume vs. Value: Volume growth was approximately 6%, while value growth was 10% for Q2.

Segment-wise Performance (Q2 FY27):
Geographic Contribution: North India (31%), East India (12%), West India (28%), South India (29%).
Product Category Contribution: Insecticides (47%), Fungicides (25%), Herbicides (8%), Others (20%).

Forward-Looking Statements & Guidance:
Management maintained its single-digit growth guidance for FY27.
For H2 FY27, they expect low single-digit revenue growth and anticipate a gross margin contraction of ~100 bps, partly due to the impact of GST refund accounting.
The initial movement for the upcoming Rabi season was described as promising in certain regions, with performance hinging on South and East zones.

Strategic and Operational Updates:
Dahej Plant: H1 FY27 sales were ~INR 55 crores with a reduced EBITDA loss of INR 1.79 crores (vs. INR 3.5 crores in H1 FY26). Capacity expansion is planned to add two new fungicide products for the Indian market by FY28.
International Business: Customer appointments have been made in 14 countries, with purchase orders received from 5 countries.
Product Launches: The biostimulant product Dhanzyme Gold (liquid) received approval and is planned for launch in December 2026. Biostimulant sales in Q2 were INR 11.7 crores (vs. INR 8.4 crores in Q2 FY26).
Key Products: Products like LaNevo, Miyako, Mortar (insecticides), and MYCORe Super (biostimulant) were highlighted as key growth drivers.

The regulatory filing included the enclosed transcript of the conference call as an attachment (Encl: a/a).

The announcement itself did not disclose any new financial data; it was an intimation of the availability of the call transcript. The financial figures summarized above were extracted from the discussion within the attached transcript.

Logistical details like dial-in numbers were part of the transcript but are excluded from this summary as per instructions.